Catch up on any of the neurology headlines you may have missed in August 2026, compiled into 1 place by the NeurologyLive® team.
News|Articles|June 10, 2026
FDA Action Update, May 2026: Approvals, Priority Review, and Extension of Review
Author(s)Isabella Ciccone, MPH
Catch up on any of the neurology headlines you may have missed in May 2026, compiled into 1 place by the NeurologyLive® team.
Advertisement
Advertisement
The FDA was busy in May 2026, making a number of decisions on potential new therapeutic agents, including accepting a resubmission, granting a clearance, and issuing a complete response letter.
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 4, 2026.
Microstructure Imaging has announced that the FDA cleared its MICSI-PET, an MR-guided PET enhancement platform with automated amyloid Centiloid and tau quantification.
FDA approval of apitegromab introduces a muscle-targeting approach to SMA treatment, with phase 3 data demonstrating motor-function benefit when added to existing SMN2-directed therapies.
The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare autoimmune disease.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement